Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$171.63
+1.1%
$178.25
$163.33
$251.99
$48.64B0.252.02 million shs2.90 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$87.57
+9.7%
$80.70
$57.52
$117.19
$31.31B1.464.37 million shs10.20 million shs
ResMed Inc. stock logo
RMD
ResMed
$256.06
+0.6%
$242.35
$180.34
$263.05
$37.32B0.78980,610 shs993,727 shs
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$334.75
$332.85
$157.00
$334.90
$12.57B0.88968,088 shsN/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
+1.12%+0.95%+0.08%-24.71%-27.25%
DexCom, Inc. stock logo
DXCM
DexCom
+9.68%+7.01%+3.62%+21.41%-20.80%
ResMed Inc. stock logo
RMD
ResMed
+0.71%+2.37%+5.36%+15.39%+40.41%
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.9458 of 5 stars
4.24.03.34.02.62.51.3
DexCom, Inc. stock logo
DXCM
DexCom
4.8119 of 5 stars
3.55.00.04.72.22.51.9
ResMed Inc. stock logo
RMD
ResMed
4.1513 of 5 stars
2.31.03.34.62.71.71.3
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.36
Hold$219.2227.73% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.95
Moderate Buy$98.5012.48% Upside
ResMed Inc. stock logo
RMD
ResMed
2.64
Moderate Buy$259.331.28% Upside
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SWAV, BDX, RMD, and DXCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
DexCom, Inc. stock logo
DXCM
DexCom
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$102.00
6/3/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$261.00 ➝ $241.00
5/30/2025
DexCom, Inc. stock logo
DXCM
DexCom
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$104.00
5/22/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$217.00 ➝ $185.00
5/22/2025
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00 ➝ $102.00
5/20/2025
ResMed Inc. stock logo
RMD
ResMed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$286.00
5/6/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$280.00 ➝ $196.00
5/5/2025
DexCom, Inc. stock logo
DXCM
DexCom
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$90.00 ➝ $93.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$280.00 ➝ $224.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$260.00 ➝ $185.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$192.00
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$20.18B2.44$21.37 per share8.03$89.57 per share1.92
DexCom, Inc. stock logo
DXCM
DexCom
$4.03B8.51$2.47 per share35.52$5.38 per share16.28
ResMed Inc. stock logo
RMD
ResMed
$4.69B8.01$9.28 per share27.58$33.11 per share7.73
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$787.97M15.95$4.31 per share77.61$20.02 per share16.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.71B$5.2432.7510.971.287.28%15.99%7.36%8/7/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.3465.3535.601.7012.90%30.05%10.00%7/24/2025 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$1.02B$8.9128.7424.721.7526.15%25.67%18.59%7/30/2025 (Estimated)
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$147.28M$4.2878.2154.342.4320.75%24.79%11.95%N/A

Latest SWAV, BDX, RMD, and DXCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q2 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.28$3.35+$0.07$1.06$5.35 billion$5.27 billion
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billion
4/23/2025Q3 2025
ResMed Inc. stock logo
RMD
ResMed
$2.36$2.37+$0.01$2.48$1.28 billion$1.29 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.162.42%N/A79.39%53 Years
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$2.120.83%N/A23.79%13 Years
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
N/AN/AN/AN/AN/A

Latest SWAV, BDX, RMD, and DXCM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.042.02%6/9/20256/9/20256/30/2025
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.9%5/8/20255/8/20256/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.70
1.13
0.64
DexCom, Inc. stock logo
DXCM
DexCom
0.55
1.50
1.32
ResMed Inc. stock logo
RMD
ResMed
0.12
3.41
2.49
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
0.97
13.81
12.61

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
ResMed Inc. stock logo
RMD
ResMed
54.98%
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
95.35%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.36%
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
ResMed Inc. stock logo
RMD
ResMed
0.71%
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
3.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
74,000286.61 million285.58 millionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
10,300392.11 million390.85 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
9,980146.63 million145.59 millionOptionable
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
1,46837.54 million36.27 millionOptionable

Recent News About These Companies

Shockwave E8 Peripheral IVL Catheter Launched

New MarketBeat Followers Over Time

Media Sentiment Over Time

Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$171.63 +1.91 (+1.12%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$171.57 -0.06 (-0.03%)
As of 06/24/2025 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

DexCom stock logo

DexCom NASDAQ:DXCM

$87.57 +7.73 (+9.68%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$87.64 +0.07 (+0.08%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

ResMed stock logo

ResMed NYSE:RMD

$256.06 +1.54 (+0.60%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$257.25 +1.19 (+0.47%)
As of 04:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Shockwave Medical stock logo

Shockwave Medical NASDAQ:SWAV

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.